Industry News

Novartis nabs FDA approval for delayed MS drug

The company’s Sandoz division now has U.S. approval for a larger dosage of its multiple sclerosis drug Glatopa, which ends a delay that has seen its rival generics sneak past to market.

Read more: Novartis nabs FDA approval for delayed MS drug